Search results
Study highlights need for cell-type-specific thera | Newswise
Newswise· 2 days agoResearchers from the University of Illinois have demonstrated the importance of cell-type-specific...
A Shaggy, Sting-y night by the ocean raises more than $4 million for AIDS research
The Palm Beach Post via Yahoo News· 1 day agoShe then introduced the chairs, who noted that a cure for HIV was still urgently needed and reminded guests that the night was all about raising money.
Q&A: Scientist partners with colleagues around the globe to make gene therapies more effective and...
Medical Xpress· 3 days agoIn a Q&A, Adair discusses the promise of gene therapies to cure an array of diseases, as well as the need for stakeholders around the world to join forces to develop the best ...
Celebrity News | Entertainment News | TMZ.com
TMZ· 2 days agoArticles - April, 2020 Chris Cuomo Says COVID-19 Feeling Like Flu So Far, Fears for His Family Guess Who This Cute Kid Turned Into! George Foreman Counseled Wilder After Fury Fight, Just Like 'Rumble In The Jungle'
Alberta First Nations health centre will join study aiming to get people tested for syphilis
CBC via Yahoo News· 5 days agoHealth officials are teaming up to make syphilis testing more accessible to people living in central...
UTSW Research: Improved bladder cancer detection, | Newswise
Newswise· 3 days agoBlue light improves bladder cancer detection across races; Gamma waves distinguish goal-oriented...
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agoWhile these products have been successful, this dependence makes the company vulnerable to market...
Don’t Trust That ‘Veneer Tech’
The Cut· 4 days agoTyrisha Ragin wanted an icy-white smile. As she scrolled social media, she found a business run by a charismatic woman known as Princess offering veneers...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 3 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...
